Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 5
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA, Viswanadhapalli S, Mann M, Chakravarty D, Krishnan S, Liu Z, Liu J, Pratap UP, Ebrahimi B, Sanchez JR, Li X, Ma S, Park BH, Santhamma B, Chen Y, Lai Z, Raj GV, Yuan Y, Zhou D, Sareddy GR, Tekmal RR, McHardy S, Huang TH, Rao MK, Vankayalapati H, Vadlamudi RK. Altwegg KA, et al. Cancer Res. 2022 Oct 17;82(20):3830-3844. doi: 10.1158/0008-5472.CAN-22-0698. Cancer Res. 2022. PMID: 35950923 Free PMC article.
Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34.
Altwegg KA, Pratap UP, Liu Z, Liu J, Sanchez JR, Yang X, Ebrahimi B, Panneerdoss DM, Li X, Sareddy GR, Viswanadhapalli S, Rao MK, Vadlamudi RK. Altwegg KA, et al. Breast Cancer Res Treat. 2023 Jul;200(1):151-162. doi: 10.1007/s10549-023-06958-4. Epub 2023 May 18. Breast Cancer Res Treat. 2023. PMID: 37199805 Free PMC article.
Targeting aberrant replication and DNA repair events for treating breast cancers.
Rajamanickam S, Park JH, Subbarayalu P, Timilsina S, Bates K, Yadav P, Nirzhor SSR, Eedunuri V, Mohammad TA, Jung KH, Onyeagucha B, Abdelfattah N, Benevides R, Lee G, Chen Y, Vadlamudi R, Brenner A, Kaklamani V, Jatoi I, Kuhn J, Hromas R, Gupta YK, Kaipparettu BA, Arbiser JL, Rao MK. Rajamanickam S, et al. Commun Biol. 2022 May 24;5(1):493. doi: 10.1038/s42003-022-03413-w. Commun Biol. 2022. PMID: 35610507 Free PMC article.
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.
Tang W, Ramasamy K, Pillai SMA, Santhamma B, Konda S, Pitta Venkata P, Blankenship L, Liu J, Liu Z, Altwegg KA, Ebrahimi B, Pratap UP, Li X, Valente PT, Kost E, Sareddy GR, Vadlamudi RK, Nair HB, Tekmal RR, Viswanadhapalli S. Tang W, et al. Cell Death Discov. 2021 Aug 16;7(1):216. doi: 10.1038/s41420-021-00603-z. Cell Death Discov. 2021. PMID: 34400617 Free PMC article.
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Pratap UP, Sareddy GR, Liu Z, Venkata PP, Liu J, Tang W, Altwegg KA, Ebrahimi B, Li X, Tekmal RR, Viswanadhapalli S, McHardy S, Brenner AJ, Vadlamudi RK. Pratap UP, et al. Neurooncol Adv. 2021 Jul 17;3(1):vdab099. doi: 10.1093/noajnl/vdab099. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34485908 Free PMC article.
11 results